Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, February 25, 2020 at 4:30 p.m. EDT to report its financial results for the quarter and year ended December 31, 2019 and provide a corporate update. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
Q4 2019 Paratek Pharmaceuticals Inc Earnings Call
-- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million -- Paratek Now Anticipates its Cash.
If you own shares in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) then it's worth thinking about how it contributes to...
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company has entered into a license grant with Almirall (ALM) for SEYSARA® (sarecycline) for the greater China region, which includes the Peoples Republic of China, Hong Kong, and Macau. Under the terms of the agreement, Paratek will earn high single-digit royalties on net sales in the greater China region. Almirall plans to develop sarecycline for acne in China, with a potential submission to the China National Medical Products Administration in 2023.
As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals
Shareholders in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) had a terrible week, as shares crashed 37% to US$2.92 in...
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that a pre-emergency use authorization (EUA) application for NUZYRA• (omadacycline) has been submitted to the U.S. Food and Drug Administration (FDA). With a pre-EUA, FDA could allow for the potential use of NUZYRA during a declared emergency under emergency use authorization for the treatment and prophylaxis of pulmonary anthrax in a public health emergency.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March 31, 2020 and provide a corporate update. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 40.00% year over year to ($0.66), which beat the estimate of ($0.80).Revenue of $7,920,000 higher by 395.62% year over year, which beat the estimate of $7,460,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on PRTKRevenue guidance hasn't been issued by the company for now.Price Action Company's 52-week high was at $5.8952-week low: $2.50Price action over last quarter: Up 9.95%Company Profile Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. Omadacycline is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. Sarecycline is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.See more from Benzinga * Recap: New Age Beverages Q1 Earnings * Recap: Synchronoss Technologies Q1 Earnings * Arbutus Biopharma: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support all of the U.S. Food and Drug Administration (FDA) post-marketing requirements associated with the approval of NUZYRA including pneumonia and pediatric studies as well as the five-year post-marketing bacterial surveillance study. In connection with the FDA approval of NUZYRA in October 2018, the FDA required that Paratek complete post-marketing pediatric studies examining the safety and efficacy of NUZYRA in children ages eight to 17 years.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support the onshoring of Paratek manufacturing activities for NUZYRA. In December 2019, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, awarded Paratek a five-year contract, valued at up to $285 million, to support: 1) the development of NUZYRA for the treatment of pulmonary anthrax; 2) all of the U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; 3) U.S. onshoring and manufacturing security requirements and 4) the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the Jefferies 2020 Virtual Healthcare Conference, Wednesday, June 3, 2020 at 8:00 a.m. ET. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/jeff126/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that on February 28, 2020, the Company granted stock options and restricted stock units to two new employees of the Company. The stock options are to acquire, in the aggregate, 21,100 shares of the Company’s common stock at a per share exercise price of $4.78, the closing sales price on February 28, 2020, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at Bank of America Securities 2020 Health Care Conference, Wednesday, May 13, 2020 at 11:40 a.m. ET. To access the live webcast of Paratek's presentation, please visit http://www.veracast.com/webcasts/bofa/healthcare2020/id57206441686.cfm. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
-- Announced Initiation of Funding from BARDA for All FDA Required Post-Marketing Studies and Security Requirements and U.S. Onshoring of an Additional Manufacturing.
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at SVB Leerink 9th Annual Global Healthcare Conference today, Wednesday, February 26, 2020 at 3:00 p.m. ET at the Lotte New York Palace Hotel in New York. To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/svbleerink34/prtk/. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The investors in Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) will be rubbing their hands together with glee today...
Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?